TB CARE - FHI 360 Care...  CB-DOTS Community-Based DOTS CBTBC Community-Based TB Care ... SOP...

download TB CARE - FHI 360 Care...  CB-DOTS Community-Based DOTS CBTBC Community-Based TB Care ... SOP Standard

of 39

  • date post

    19-Aug-2018
  • Category

    Documents

  • view

    213
  • download

    0

Embed Size (px)

Transcript of TB CARE - FHI 360 Care...  CB-DOTS Community-Based DOTS CBTBC Community-Based TB Care ... SOP...

  • 1

    TB CARE IPROGRAM YEAR 2

    Third Quarter Performance Monitoring ReportApril 1st, 2012 June 30th, 2012

    August 15, 2012

    TB CARE

  • 2

    TB CARE I Partners

    American Thoracic Society (ATS)FHI 360

    Japan Anti-Tuberculosis Association (JATA)KNCV Tuberculosis Foundation (KNCV)

    Management Sciences for Health (MSH)International Union Against Tuberculosis and Lung Disease (The Union)

    World Health Organization (WHO)

  • 3

    ContentsList of Abbreviations ............................................................................................................................. 41. Introduction .............................................................................................................................. 62. Project Management Unit (PMU) .................................................................................................. 72.1 Knowledge Exchange .................................................................................................................. 83. Core projects ............................................................................................................................ 94. Country projects ........................................................................................................................ 20 PMDT ....................................................................................................................................... 20 GeneXpert ................................................................................................................................ 22 Tuberculosis in Children ............................................................................................................. 234.1 Afghanistan .............................................................................................................................. 234.2 Botswana.................................................................................................................................. 244.3 Cambodia ................................................................................................................................. 244.4 CAR-Kazakhstan ........................................................................................................................ 254.5 CAR-Kyrgyzstan ......................................................................................................................... 254.6 CAR-Tajikistan ........................................................................................................................... 264.7 CAR-Uzbekistan ......................................................................................................................... 264.8 Djibouti .................................................................................................................................... 264.9 Dominican Republic .................................................................................................................... 274.10 Ethiopia .................................................................................................................................... 274.11 Ghana ...................................................................................................................................... 284.12 Indonesia ................................................................................................................................. 294.13 Kenya ...................................................................................................................................... 294.14 Mozambique.............................................................................................................................. 304.16 Nigeria ..................................................................................................................................... 314.17 South Sudan ............................................................................................................................. 324.18 Uganda .................................................................................................................................... 334.19 Vietnam ................................................................................................................................... 344.20 Zambia ..................................................................................................................................... 344.21 Zimbabwe ................................................................................................................................. 355. Regional Projects ....................................................................................................................... 365.1 Center of Excellence (CoE) for PMDT ............................................................................................ 365.2 East Africa Supranational Reference Laboratory (SNRL) ................................................................... 365.3 ECSA (East, Central and Southern Africa) ...................................................................................... 365.4 Central Asian Republic (CAR) Regional Funding .............................................................................. 365.5 Kenya Lung Conference .............................................................................................................. 37

    Table

    Table 1: Summary of visitors to the TB CARE I website: ............................................................................. 8Table 2: Completed Year 1 Core Projects and Deliverables, through March 2012 ............................................ 10Table 3: Overview of Extended Year 1 Core Projects, January 2012 to March 2012 ........................................ 11Table 4: Overview of Approved Year 2 Core Projects, January 2012 to March 2012 ........................................ 12Table 5: MDR-TB cases diagnosed by drug sensitivity testing and put on SLD treatment as of June 2012 .......... 21Table 6: Number of GeneXpert tests performed through June 30, 2012 ........................................................ 22Table 7: TB CARE I-funded procurements of GeneXpert instruments and cartridges as of June 2012 ................ 22

    Figures

    Figure 1 Countries where visits to the website came from and the number of visitors per country. .................. 8Figure 2: Map of TB CARE I countries, as of June 2012 .............................................................................. 20Figure 3: Contribution of Urban DOTS in new SS+ TB Cases in Kabul, 2009-2011 ......................................... 24Figure 4: Proportion of referred TB suspects reporting to public health facilities (%) ...................................... 24Figure 5: Trends in number TB laboratory coverage in S. Sudan 2005 - 2012 ................................................ 32

  • 4

    List of Abbreviations

    ACSM Advocacy Communication Social MobilizationAFB Acid Fast BacilliART Anti-retroviral TherapyBinfar Directorate General of Pharmaceutical and Medical Devices (Indonesia)BPPM Directorate of Medical Services (Indonesia)CAR Central Asian RepublicsCB-DOTS Community-Based DOTSCBTBC Community-Based TB CareCDC Center for Disease Control and PreventionCoE Center of ExcellenceCDR Case Detection RateCSO Civil Society OrganizationDEWG DOTS Expansion Working GroupDOT Directly Observed TreatmentDOTS Directly Observed Treatment Short CourseDR Drug ResistanceDRS Drug Resistance SurveyDST Drug Susceptibility TestingECSA East, Central and Southern AfricaEQA External Quality AssuranceERR Electronic Recording & ReportingFIND Foundation for Innovative New DiagnosticsGDF Global Drug FacilityGFATM Global Fund for Aids, Tuberculosis and MalariaGLC Green Light CommitteeGLI Global Laboratory InitiativeHRD Human Resource DevelopmentHSS Health System StrengtheningIC Infection ControlIEC Information, Education and CommunicationIQC Internal Quality ControlILEP International Federation of Anti-Leprosy AssociationsJATA Japan Anti Tuberculosis AssociationJSM Joint Strategic MeetingKANCO Kenya AIDS NGOs ConsortiumKAPTLD Kenya Association for Prevention of TB and Lung DiseasesKIT Royal Tropical Institute KNCV KNCV Tuberculosis FoundationLED Light Emitting Diode (microscopy)LPA Line Probe AssayMDR Multi Drug ResistanceMDR-TB Multi Drug Resistant Tuberculosis M&E Monitoring and EvaluationMOA Memorandum of AgreementMOH Ministry of HealthMOST Management & Organizational Sustainability ToolMSF Mdecins sans Frontires (Doctors without Borders)MSH Management Sciences for HealthNAP National Aids ProgramNCE No-Cost ExtensionNGO Non-Governmental OrganizationNIHE National Institute of Health and Epidemics (Vietnam)NTP National TB ProgramNRL National Reference LaboratoryNTRL National Tuberculosis Reference LaboratoryOPD Out-patient DepartmentOR Operations ResearchPCA Patient Centered ApproachPITC Provider-Initiated Treatment and CounselingPHCC Primary Health Care CenterPLHIV People Living with HIVPMDT Programmatic Management of Drug-resistant TuberculosisPMU Program Management UnitPPM Private Public MixPPP Public Private PartnershipRIF RifampicinQMR Quarterly Monitoring ReportSANAS South Africa National Accreditation SystemSLD Second Line Drug

  • 5

    SNRL Supra National Reference LaboratorySOP Standard Operating ProceduresSS+ Sputum Smear positiveSS- Sputum Smear negativeTA Technical AssistanceTB TuberculosisTB IC TB Infection ControlTB CAP Tuberculosis Control Assistance ProgramTBCTA Tuberculosis Coalition for Technical AssistanceTOT Training of TrainersTFM Transitional Funding MechanismTWG Technical Working GroupUSAID United States Agency for International DevelopmentUVGI Ultraviolet Germicida